Citicoline para Attention & Focus Difficulties

B Evidências Pelo menos um ensaio aleatorizado apoia esta conclusão, com resultados maioritariamente consistentes.

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Conclusão

Key Study Findings

Randomized Controlled Trial Double-blind

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.

Dose: None vs: placebo Outcome: ADHD symptom improvement Efeito: None None

População: pediatric patients aged 7-12 years diagnosed with ADHD

Other 12 weeks

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.

Dose: 19.17% vs: None Outcome: cognitive function Efeito: None None

População: Covid-19 during the pandemic period between 2020 and 2022

Systematic Review n=8137

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.

Dose: None vs: None Outcome: Cocaine craving reduction Efeito: None None

População: Cocaine use disorder patients

Review

Cholinergic nervous system and glaucoma: From basic science to clinical applications.

Dose: None vs: None Outcome: Mortality Efeito: None None

População: None

Review

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].

Dose: None vs: None Outcome: None Efeito: None None

População: None

Key Statistics

Estudos

1600

Participantes

↑

Positive

Nota

Referenced Papers

Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. RCT

Clinical neuropharmacology None 2 citações

Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. Other

Diagnostics (Basel, Switzerland) 2023

Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. Review

Brain sciences 2022 17 citações

Cholinergic nervous system and glaucoma: From basic science to clinical applications. Review

Progress in retinal … 2019 107 citações

[X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. Review

Revista de neurologia 2012 12 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:: 250-500 mg/day
cognitivesupport:: 500-2,000 mg/day

Limite superior: Well-tolerated up to 4,000 mg/day in clinical trials

Dosagens Estudadas em Pesquisas

Dosagem	Duração	Efeito	N
None	--	Neutral	--
19.17%	12 weeks	Positive	--
None	--	Mixed	8137
None	--	Positive	--
None	--	Mixed	--

Melhor horário: Morning or split dose; can be taken with or without food

Safety & Side Effects

Efeitos Colaterais Relatados

⚠ Headache
⚠ Insomnia (if taken late in the day)
⚠ Mild gastrointestinal discomfort
⚠ Rare: restlessness or overstimulation

Interações Conhecidas

● Levodopa (may enhance dopaminergic effects)
● Cholinergic drugs (additive acetylcholine increase)
● Anticholinergics (may reduce citicoline effectiveness)

Ingestão máxima tolerável: Well-tolerated up to 4,000 mg/day in clinical trials

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Citicoline help with Attention & Focus Difficulties?

Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).

How much Citicoline should I take for Attention & Focus Difficulties?

Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Citicoline?

Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Citicoline and Attention & Focus Difficulties?

We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.

Outros ingredientes para Attention & Focus Difficulties

L-Theanine B Omega-3 Fatty Acids (DHA/EPA) C Bacopa monnieri C Phosphatidylserine C

Citicoline para outras condições

Memory Loss B

Veredito Rápido

Evidence Strength72%

High confidence

Detalhamento dos Estudos

RCT (1)Meta (0)Other (13)

Comparar Alternativas

Veja como outros ingredientes se comparam para esta condição.

Ver todos os ingredientes para Attention & Focus Difficulties

Saiba Mais

References

[1] Isabel Barros Hübner et al.. Clin Neuropharmacol. Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study. doi:10.1097/WNF.0000000000000602 PubMed
[2] Milena Dimitrova et al.. Diagnostics (Basel). 2023. Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome. doi:10.3390/diagnostics13162703 PubMed
[3] Dângela Layne Silva Lassi et al.. Brain Sci. 2022. Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review. doi:10.3390/brainsci12111546 PubMed
[4] Muneeb A Faiq et al.. Prog Retin Eye Res. 2019. Cholinergic nervous system and glaucoma: From basic science to clinical applications. doi:10.1016/j.preteyeres.2019.06.003 PubMed
[5] M Carmen Carrascosa-Romero et al.. Rev Neurol. 2012. [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion]. PubMed

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.